Efficacy of Alogliptin as Add on Therapy with Metformin Among Inadequately Control Type 2 Diabetes Mellitus Patients Attending Rajshahi Diabetic Association General Hospital

Background: Globally, Type 2 diabetes mellitus (DM) is a leading cause of morbidity and mortality and oral antidiabetic medications are an essential part of the treatment plan. While long-term blood glucose management can be challenging by using monotherapy antidiabetic medications, combination therapy with various modes of action is frequently required. Methods: This quasi-experimental study was conducted in the Department of Pharmacology and Therapeutics, Rajshahi Medical College, Rajshahi in collaboration with Rajshahi Diabetic Association General Hospital (RADAS), Rajshahi on Type 2 DM patients who had inadequate glycemic control with Metformin and diet with lifestyle modification therapy. Based on predefined eligibility criteria, a total number of 42 Type 2 DM patients of both sexes were included in the study. Tablet Alogliptin 25mg as once-daily dose was added after breakfast to the ongoing treatment of tablet Metformin 1000mg for each patient and was followed up at the end of 4, 8 and 12 weeks of drug administration. Results: Most (92.90%) of the patients had diabetes ≥ 1-year duration. After administration of Alogliptin as add on therapy with Metformin, overall reduction of FBS, PPBS and HbA1c from baseline to 12 weeks of intervention was found statistically highly significant (p < 0.001 in each case). Conclusions: So, Alogliptin with metformin might be used as an 1st line oral antidiabetic drug in case of inadequately control Type 2 diabetes mellitus patients.